Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Influenza Diagnostics Market Research Report Information By Type of Flu (Type A Flu, Type B Flu, and Type C Flu), By Test Type (Traditional Diagnostic Tests and Molecular Diagnostic Tests), By End User (Hospitals & Clinical Laboratories) - Forecast till 2032


ID: MRFR/MED/2264-CR | 153 Pages | Author: Rahul Gotadki| April 2019

Influenza Diagnostics Market Overview


Market Research Future (MRFR) studied the Influenza Diagnostics Market is expected to reach USD 1.81 Billion by 2032 at CAGR 5.3% during the forecast period 2023-2032.


A contagious respiratory infection induced by several flu viruses is called influenza. Every year, a large number of people is afflicted with seasonal influenza that result in hospitalizations and flu-related deaths of a large number of people, especially the aging patient population.


COVID-19 Analysis


The impact evaluation of the influenza diagnosis market for COVID-19 is recorded in the report. The report details the impact of new policies by governments on the healthcare field due to the pandemic. The outbreak of COVID 19 has detrimental effect on the world health and medical system. The report describes solutions that are deployed to counter the decline in healthcare system of the world. Other major issues are elaborated in detail in the report.


Influenza Diagnostics Market Trends


DriversGrowing Prevalence of Influenza to Support Market Rise

The growing prevalence of influenza creating the need to deliver effective treatment can favor the expansion of the influenza diagnostic market. In addition, a rise in funding for research in influenza diagnosis can add to the market expansion. The fast-growing demand for quick diagnostic solutions can favor market expansion in the years to come. The increase in awareness about such disease and the introduction of quadrivalent influenza vaccines can drive the influenza diagnostics market in the coming years.


OpportunitiesStartups Explore Untapped Market Potential

The emergence of startups exploring the untapped potential of the market can contribute to the creating of numerous revenue generation pockets for the market by 2023. The introduction of disruptive technologies, such as artificial intelligence, favoring innovations in diagnostic solutions can support the market rise.


RestraintsHike in Medical Care Cost to Inhibit Market Growth

The gradual rise in healthcare expenses and issues with inaccuracy in diagnostic solutions can hinder the influenza diagnostics market rise in the years to come.


Influenza Diagnostics Market Segment Insights


Influenza Diagnostics Type of Flu Insights


The type A flu segment can rise at a substantial pace with decent CAGR. The segment can acquire a USD 954.512 Million influenza diagnostics market share by 2023. The type B flu segment can rise at 8.66% CAGR from 2018 to 2023. The increase in initiatives by the government to curb influenza is likely to boost market growth.


Influenza Diagnostics Test Type Insights


The molecular diagnostic tests segment can exhibit the highest CAGR along the evaluation tenure as physicians are inclined towards accurate diagnostic solutions. The traditional diagnostics segment can also thrive in the approaching years.


Influenza Diagnostics End-User Insights


The point of care testing segment can retain the leading position in the global influenza diagnostics market by 2023. The segment can exhibit decent CAGR through the analysis tenure. An increase in number of clinicals dedicated to diagnosis and treatment of influenza can drive the hospital and clinical laboratories segment growth.


Influenza Diagnostics Regional Insights


Americas Market to Thrive by 2023

In Americas, the influenza diagnostics market can secure 38.0% share of the global market value by 2023. The regional influenza diagnostics market can thrive across the forecast tenure due to increase in prevalence of influenza and the ease of availability of advanced healthcare facilities.


EU Influenza Diagnostics to Gain Momentum

In Europe, the aviation test equipment market can secure the second-largest share of the global market. The rise in count of pharmaceutical companies dealing in exporting their products is also responsible for growth of the regional market. Rise in disease awareness, and extended recommendations by advisory bodies and governmental for vaccination against influenza can contribute to the market upsurge.


APAC Market to Hold Forefront Position

Asia Pacific influenza diagnostics market can secure the forefront position in the global lead. This can be attributed to rapid development in healthcare infrastructure and growing prevalence of endocrinology, lymphatic systems, cardiovascular, and respiratory disorders.


Competitive Landscape


MRFR enlisted renowned companies that are operating in the global influenza diagnostics market. The competitive analysis of the influenza diagnostics market consists of market share analysis, financial analysis, and product benchmarking. Alongside, strategic developments in the market that include mergers & acquisitions, product launches, and joint ventures are also studied by MRFR analysts that can help in understanding regional progress and growth scopes offered by these enterprises.


List of Key Companies Covered in this Report



  • Coris BioConcept

  • DiaSorin S.p.A

  • Alere Inc.

  • Lonza

  • Ortho-Clinical Diagnostics

  • Qiagen

  • Wako

  • Abbott

  • Analytik Jena AG

  • Becton, Dickinson and Company,

  • Biocartis,

  • bioM√©rieux Inc,

  • Cepheid,

  • DiaSorin S.p.A., F.

  • Hoffmann-La Roche Ltd,

  • GenMark Diagnostics, Inc.,

  • Luminex Corporation,

  • Meridian Bioscience, Inc.,

  • Quidel Corporation,

  • SA Scientific,

  • Thermo Fisher Scientific Inc.


Recent Developments




  • February 2023-¬†The Molecular Diagnostic System is a powerful tool for quickly identifying and distinguishing between COVID-19, the flu, and RSV. By taking a single nasal swab or a single nasopharyngeal swab sample, it can analyze the sample and provide results in as little as two hours. This makes it incredibly useful for quickly diagnosing and treating patients with the most appropriate care. Furthermore, the system is highly accurate, meaning that patients can be confident that they are receiving the right diagnosis and treatment. The Molecular Diagnostic System is an invaluable tool in the fight against the spread of infectious diseases like COVID-19, the flu, and RSV.


  • January 2021-Labs that are performing Flu SC2 Multiplex Assay recognized by the Centers for Disease Control‚Äôs (CDC), which is a single test to diagnose infection caused due to influenza A, SARS-CoV-2, or influenza B, can now use a Promega nucleic acid purification kit and two Promega instruments. Promega is a Wisconsin-based producer of enzymes and other types of molecular biology and biotechnology portfolio


  • January 2021-GeneIQ, a Texas-based molecular diagnostics laboratory that offer COVID-19 testing across the country, announced the introduction of combined PCR test for influenza A (Flu A), viruses SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV), and influenza B (Flu B).


Influenza Diagnostics Market Segmentation


Market analysis, sizing, and forecast of the influenza diagnostics market are covered in the report. The country-level assessment of the market and associated forecasts are explained in the influenza diagnostics market report. The expansion of the influenza diagnostic controlling market dynamics intelligence that includes, market drivers, opportunities, supply chain, restraints, trends, value chain analysis, and Porter’s five forces are studied by MRFR analysts. Patent analysis outlook, Technology trends, and regulatory landscape of the market is detailed in the report to help investors acquire an in-depth understanding of the market and associated activities.


Influenza Diagnostics Type of Flu Outlook



  • Type A Flu

  • Type B Flu

  • Type C Flu


Influenza Diagnostics Test Type Outlook



Influenza Diagnostics End-User Outlook



  • Hospitals & Clinical Laboratories

  • Point-of-Care Testing

Report Attribute/Metric Details
  Market Size   USD 1.81 Billion
  CAGR   5.3%
  Base Year   2021
  Forecast Period   2023-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type of Flu, Test Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Coris BioConcept, DiaSorin S.p.A, Alere Inc., Lonza, Ortho-Clinical Diagnostics, Qiagen, Wako, Abbott, Analytik Jena AG, Becton, Dickinson and Company, Biocartis, bioMérieux Inc, Cepheid, DiaSorin S.p.A., F., Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., Luminex Corporation, Meridian Bioscience, Inc., Quidel Corporation, SA Scientific, Thermo Fisher Scientific Inc.
  Key Market Opportunities   Startups Explore Untapped Market Potential
  Key Market Drivers   Growing Prevalence of Influenza to Support Market Rise


Frequently Asked Questions (FAQ) :

The global influenza diagnostics market is expected to reach a valuation of USD 1.81 Billion by 2032.

The global market is expected to exhibit a strong 5.3% CAGR over the forecast period from 2023 to 2032

The growing prevalence of influenza is the major driver for the market.

The Americas accounted for the largest market share of 38% in 2017.

Leading players in the influenza diagnostics market include Abbott, Becton Dickinson and Company, DiaSorin SpA, Cepheid, and Thermo Fisher Scientific, among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.